These results confirm that in vivo, LRP1–SNRNP25 overexpression may promote tumor growth by increasing the pJNK level and that the pJNK inhibitor SP600125 can significantly inhibit tumor growth induced by LRP1–SNRNP25 overexpression. This evidence concerns the gene LRP1 and neoplasm.